Amylyx Pharmaceuticals (AMLX) Total Current Liabilities (2021 - 2025)
Historic Total Current Liabilities for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $25.8 million.
- Amylyx Pharmaceuticals' Total Current Liabilities fell 5216.36% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.8 million, marking a year-over-year decrease of 5216.36%. This contributed to the annual value of $28.4 million for FY2024, which is 6537.63% down from last year.
- Per Amylyx Pharmaceuticals' latest filing, its Total Current Liabilities stood at $25.8 million for Q3 2025, which was down 5216.36% from $21.4 million recorded in Q2 2025.
- Amylyx Pharmaceuticals' Total Current Liabilities' 5-year high stood at $91.6 million during Q1 2024, with a 5-year trough of $17.4 million in Q4 2021.
- In the last 5 years, Amylyx Pharmaceuticals' Total Current Liabilities had a median value of $39.1 million in 2022 and averaged $44.0 million.
- Per our database at Business Quant, Amylyx Pharmaceuticals' Total Current Liabilities surged by 16792.94% in 2022 and then crashed by 8043.19% in 2025.
- Over the past 5 years, Amylyx Pharmaceuticals' Total Current Liabilities (Quarter) stood at $17.4 million in 2021, then surged by 167.93% to $46.6 million in 2022, then skyrocketed by 76.02% to $82.0 million in 2023, then tumbled by 65.38% to $28.4 million in 2024, then dropped by 9.21% to $25.8 million in 2025.
- Its Total Current Liabilities was $25.8 million in Q3 2025, compared to $21.4 million in Q2 2025 and $17.9 million in Q1 2025.